Research Paper Volume 16, Issue 3 pp 3007—3020

ITGB2 fosters the cancerous characteristics of ovarian cancer cells through its role in mitochondrial glycolysis transformation

Guo-Wei Li1, , Yan-Ping Jin2, , Jian-Ping Qiu3, , Xiu-Fang Lu3, ,

  • 1 Department of Rehabilitation Science, Nanjing Normal University of Special Education, Nanjing, Jiangsu 210000, China
  • 2 Department of Obstetrics and Gynecology, Zhongda Hospital Jiangbei Branch, School of Medicine, Southeast University, Nanjing, Jiangsu 210000, China
  • 3 Department of Obstetrics and Gynecology, Suzhou Municipal Hospital North, Suzhou, Jiangsu 215000, China

Received: September 29, 2023       Accepted: December 27, 2023       Published: February 11, 2024      

https://doi.org/10.18632/aging.205529
How to Cite

Copyright: © 2024 Guo-Wei et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Related studies have shown that ITGB2 mediates mitochondrial glycolytic transformation in cancer-associated fibroblasts and participates in tumor occurrence, metastasis and invasion of cancer cells. Based on these studies, we tried to construct a mitochondrial glycolysis regulatory network and explored its effect on mitochondrial homeostasis and ovarian cancer cells’ cancerous characteristics. Our research revealed a distinct increase in the expression of ITGB2 and associated signaling pathway elements (PI3K-AKT-mTOR) in cases of ovarian cancer. ITGB2 might control mTOR expression via the PI3K-AKT pathway, thus promote mitochondrial glycolysis transformation and cell energy supply in ovarian cancer. This pathway could also inhibit mitophagy, maintain mitochondrial stability, and enhance the cancerous characteristics in case of ovarian cancer cells by mediating mitochondrial glycolytic transformation. Thus, we concluded that ITGB2-associated signaling route (PI3K-AKT-mTOR) may contribute to the progression of cancerous traits in ovarian cancer via mediating mitochondrial glycolytic transformation.

Abbreviations

NC: normal control; TNBC: triple-negative breast cancer; CLL: chronic lymphocytic leukemia; AML: acute myeloid leukemia; FIGO: International Federation of Gynecology and Obstetrics; MMP: mitochondrial membrane potential; PMSF: phenylmethylsulfonyl fluoride.